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Abstract
Purpose of Review To review the current status of positron
emission tomography (PET) molecular imaging research
of levodopa-induced dyskinesias (LIDs) in Parkinson’s
disease (PD).
Recent Findings Recent PET studies have provided robust
evidence that LIDs in PD are associated with elevated and
fluctuating striatal dopamine synaptic levels, which is a con-
sequence of the imbalance between dopaminergic and seroto-
nergic terminals, with the latter playing a key role in
mishandling presynaptic dopamine release. Long-term expo-
sure to levodopa is no longer believed to solely induce LIDs,
as studies have highlighted that PD patients who go on to
develop LIDs exhibit elevated putaminal dopamine release
before the initiation of levodopa treatment, suggesting the
involvement of other mechanisms, including altered neuronal
firing and abnormal levels of phosphodiesterase 10A.
Summary Dopaminergic, serotonergic, glutamatergic,
adenosinergic and opioid systems and phosphodiesterase
10A levels have been shown to be implicated in the develop-
ment of LIDs in PD. However, no system may be considered
sufficient on its own for the development of LIDs, and the
mechanisms underlying LIDs in PD may have a multisystem
origin. In line with this notion, future studies should use mul-
timodal PET molecular imaging in the same individuals to
shed further light on the different mechanisms underlying
the development of LIDs in PD.
Keywords Dyskinesias . Parkinson’s disease . Molecular
imaging . Positron emission tomography
Introduction
More than 50 years since its discovery [1, 2], levodopa re-
mains the gold standard in the management of motor symp-
toms of Parkinson’s disease (PD) [3]. Although several sys-
tems are affected in PD, including dopaminergic, serotonergic,
noradrenergic, cholinergic, glutamatergic, opioid and
endocannabinoid systems [4], it is the loss of dopamine within
the nigrostriatal pathway that leads to the emergence of the
cardinal motor symptoms of PD [5]. Exogenous levodopa
therapy fundamentally restores synaptic dopamine levels in
the striatum, which is essential for the correct execution of
movements [6]. However, despite its efficacy, long-term levo-
dopa use is complicated by alterations in motor response, such
as the development of levodopa-induced dyskinesias (LIDs)
[7]. About 30% of PD patients develop LIDs after only 3 years
of levodopa use [8], and approximately 80% of PD patients
will develop LIDs over the course of the disease [9, 10].
Themechanisms underlying LIDs are still unclear. Levodopa
induces sharp increases in striatal dopamine levels, which are
particularly elevated in PD patients who experience LIDs [11].
However, the notion that LIDs are only due to high exposure to
levodopa, which progressively lowers the threshold for dyski-
nesias until the administered concentration of levodopa needed
for its antiparkinsonian action will produce LIDs, making the
responses inseparable and causing pronounced motor fluctua-
tions between an ‘on’ condition with dyskinesia and an ‘off'
condition with severe parkinsonism [12], has been questioned
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recently [13]. In PD patients who experience LIDs, the admin-
istration of a high dose of levodopa induces an antiparkinsonian
response and dyskinesias at a comparable threshold. This obser-
vation indicates that the therapeutic window between the
antiparkinsonian response and dyskinesia does not exist, except
for the period before the emergence of dyskinesia, and that also
other pathways are needed for the development of LIDs [13].
Another recent study has corroborated this hypothesis [14•].
Elevated putaminal dopamine release was present in de novo
PD patients and was associated with an increased risk of later
development of LIDs. This suggests that early compensatory
changes in striatal dopamine turnover could be a disease-
intrinsic predisposing factor for the development of LIDs, may-
be due to changes in non-dopaminergic pathways and not relat-
ed to the long-term exposure to levodopa [14•]. A large number
of studies have demonstrated that LIDs rely on a sequence of
events, including abnormalities in corticostriatal neurotransmis-
sion, postsynaptic changes in proteins and gene expression, al-
tered neuronal firing and plasticity [15, 16].
Molecular imaging modalities are able to identify minimal
alterations at the nanomolecular level, and this is a prerequisite
to understand subtle changes in brain activity [17, 18]. Positron
emission tomography (PET)molecular probes bind a target, such
as a receptor, a transporter or an enzyme, with high specificity
and power of resolution [17]. PET molecular imaging has
revolutionized the possibilities to gain insight into human brain
biology and beyond this to understand the physiology and the
pathophysiology of neurological diseases [17, 18]. PET radio-
tracers have provided invaluable insight into the mechanisms
underlying LIDs, and have been used to measure dopaminergic
[19], serotonergic [20], noradrenergic [21], cholinergic [22], glu-
tamatergic [23], adenosinergic [24], opioid [25] and cannabinoid
systems [24], phosphodiesterases [26] and other targets [27].
This review describes the current status of PET molecular
imaging of LIDs, and its relation with the underlying mecha-
nisms of PD.
Presynaptic and Postsynaptic Mechanisms of LIDs
Multiple components of the network between basal nuclei and
cortex have been recognized as a substrate for the development
of LIDs. At the molecular level, changes in signal transduction
and neurotransmission occurring in specific populations of neu-
rons have been linked to the emergence of LIDs [16].
The main component needed for the development of LIDs
is a moderate-to-severe loss of dopaminergic terminals in the
dorsal putamen, associatedwith the incapacity of the terminals
to store dopamine. In this condition, the same amount of levo-
dopa administered induces higher release of dopamine in the
extracellular space [28]. At the same time, in the absence of
enough intact dopaminergic terminals, exogenous levodopa is
metabolized in other terminals expressing the enzyme
aromatic L-amino acid decarboxylase (AADC), such as sero-
tonergic and noradrenergic terminals, which do not possess
the molecular machinery to properly control the release of
dopamine. This results in higher swings in synaptic levels of
dopamine and pulsatile stimulation of postsynaptic receptors
located on striatal projection neurons [29].
Impaired presynaptic control of dopamine release from do-
paminergic and non-dopaminergic terminals leads to
overactivation of striatal dopaminergic receptors. This is a sec-
ond component also needed for the development of LIDs.
Abnormal activation of dopaminergic receptor D1 results in hy-
peractivation of the cyclic adenosine monophosphate (cAMP)
signalling pathway [30]. D1 receptor-mediated activation of
cAMP-dependent protein kinase A (PKA) and of dopamine-
and cAMP-regulated protein of 32 kDa (DARPP-32) promotes
the stimulation of additional intracellular signalling cascades
involved in the regulation of gene transcription and protein syn-
thesis [15]. Overactivation of dopaminergic receptor D3 has also
been suggested in the development of LIDs [31].
Increased extracellular glutamate concentration [28] and
changes in the subcellular distribution of glutamate [32]
and adenosine [33] receptor subunits have also been asso-
ciated with LIDs, together with alterations in the expression
of messenger RNA that encodes the precursors of striatal
neuropeptides preproenkephalin and preprodynorphin [34].
Within the striatum, cAMP signalling is finely regulated
by phosphodiesterase 10A (PDE10A). Lesions in nigrostriatal
dopaminergic projections in animal models of PD lead to an
increase in cAMP levels [35], and treatment with levodopa
reduces the high cAMP levels observed in the denervated
striatum [35]. The cAMP levels in the corticostriatopallidal
pathway are lower at the peak of LIDs compared with those in
non-dyskinetic animals, and pretreatment with zaprinast, a
non-selective PDE10A inhibitor, prevents the reduction of
cAMP levels and reduces the severity of dyskinesias [36].
Altered striatal second-messenger signalling during dyskine-
sias may be due to the lost ability of striatal neurons to induce
both depotentiation and long-term depression [37]. Hence,
stimulation of postsynaptic striatal neurons by levodopa-
derived dopamine would fail, and dysregulation of PDE10A
could be a pathogenic mechanism underlying the dysfunction
of second-messenger signalling. We recently demonstrated
that PDE10A levels are reduced in the striatum and globus
pallidus of PD patients, and are associated with the severity of
LIDs [26]. PDE10A might be the final regulator of striatal
output, and modulation of its level may be crucial for the
control of LIDs. We illustrate these mechanisms in Fig. 1.
Molecular Imaging of the Dopaminergic System
Dopamine release can bemeasured by PETwith [11C]raclopride,
a D2 receptor antagonist radioligand which competes with
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endogenous dopamine for D2 receptor binding. Changes in D2
receptor availability, as reflected by a reduction of baseline
[11C]raclopride levels after levodopa administration, allows indi-
rect measurement of synaptic dopamine release. PD patients with
LIDs showed increased dopamine release after the administration
of levodopa compared with PD patients with stable response to
levodopa [11, 38]. Greater reduction in putaminal [11C]raclopride
levels has also been correlated with worse LIDs [39, 40••]. Also,
PD patientswith LIDs showed lower dopamine levels at 4 h from
levodopa challenge, whereas PD patients with stable response to
levodopa had unchanged putaminal dopamine levels [38]. This
indicates that LIDs are associated with increased and fluctuating
synaptic dopamine levels following levodopa administration [11,
38].
PET ligands for the presynaptic dopaminergic system such
as [18F]fluorodopa ([18F]FDOPA), [18F]dihydrotetrabenazine,
and [18F]fluoropropylcarbomethoxyiodophenylnortropane
([18F]FP-CIT) or [11C]methylphenidate ([11C]MP) are reliable
tools to assess in vivo striatal AADC activity, the density of
vesicular monoamine transporter 2 (VMAT2), and the avail-
ability of presynaptic dopamine transporters (DATs). The
AADC catalyzes the decarboxylation of levodopa to dopa-
mine, the VMAT2 is the vesicular transporter responsible for
the transport of dopamine from the cytoplasm into secretory
vesicles and a marker of dopamine storage in the dopaminer-
gic terminals, and the DAT is responsible for the high-affinity
uptake of dopamine from the synaptic cleft, respectively [41].
Putaminal AADC activity, measured by [18F]FDOPA PET,
is lower in PD patients, and correlates with the severity of
motor symptom rigidity and bradykinesia [42]. A retrospective
study was recently performed in 31 de novo PD patients who
underwent quantitative [18F]FDOPA PET to measure the effec-
tive distribution volume ratio, as a marker of dopamine release,
and who were followed up to the development of LIDs [14•].
During a mean 7-year follow-up period, 35.5% (11/31) devel-
oped LIDs. They had lower baseline effective distribution vol-
ume ratios in the putamen than those who did not develop
LIDs, indicating higher dopamine release at the baseline, inde-
pendently of the use of levodopa. PD patients with LIDs
showed 12% reduction in caudate and 28% reduction in
putaminal [18F]FDOPA uptake compared with PD patients
with a stable response to levodopa [43]. At early stages of
PD, increased uptake of [18F]FDOPA in the serotonergic and
noradrenergic terminals, which possibly reflects a compensa-
tory upregulation of AADC, has also been shown, and in the
globus pallidus internal segment, which possibly reflects dopa-
mine storage capacity [44]. A recent study with
[18F]dihydrotetrabenazine showed that in advanced PD pa-
tients, lower VMAT2 density in the caudate, putamen and
substantia nigra was correlated with the severity of motor com-
plications [45]. The increase of [18F]FDOPA uptake in the
globus pallidus internal segment is lost with the progression
of the disease in advanced PD patients with LIDs [44]. This
may indicate that a loss of dopamine storage and capacity in the
globus pallidus internal segment is also important for the de-
velopment of LIDs. The role of the globus pallidus in the de-
velopment of LIDs has also been confirmed at the postsynaptic
level [46]. PD patients with LIDs showed higher D3 receptor
levels in the globus pallidus, measured with 4-[11C]propyl-9-
hydroxynaphthoxazine PET, compared with PD patients with
stable response to levodopa [46]. This might reflect a D3 re-
ceptor upregulation in the globus pallidus and, together with
the incapacity to store dopamine, the non-ability to sustain a
normal pattern of pallidal output to motor cortex.
The presence of moderate-to-severe presynaptic dopaminer-
gic terminal loss seems to play a role also in the development of
LIDs, inducing an uncontrolled dopamine release [47]. A ret-
rospective study conducted in 127 de novo patients with PD,
who underwent [18F]FP-CIT PET at the time of diagnosis,
showed that lower putaminal DAT levels at baseline was a
predictor of the development of LIDs at the 3-year follow-up.
A study with [11C]MP PET showed that advanced PD patients
with motor fluctuations and LIDs had reduced DATexpression
in the putamen compared with advanced PD patients with mo-
tor fluctuations but no LIDs [48]. Integrity of DAT function is
central in the regulation of dopamine levels in the synaptic cleft,
and a gradual loss of DAT availability as PD progresses results
in the loss of compensatory reuptake needed when dopamine
levels substantially rise after a dose of levodopa [48].
LIDs are unlikely to result from alterations in striatal D1 or
D2 receptor availability. PD patients with LIDs and PD pa-
tients without LIDs showed no differences in striatal D1 and
D2 receptor availability, as assessed with [
11C]SCH23390
PET and [11C]raclopride PET, respectively [49].
This evidence is in support of the concept that an increased
and fluctuating dopamine release is necessary but not suffi-
cient for the development of LIDs, and other non-
dopaminergic pathways may play a role.
Molecular Imaging of the Serotonergic System
Serotonergic terminals express AADC, and are able to transform
exogenous levodopa into dopamine [50]. PET ligands for pre-
synaptic serotonergic transporter (SERT) such as
N,N-[11C]dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine
([11C]DASB) are reliable tools to assess in vivo serotonergic
terminals [51]. The serotonergic system is profoundly affected
in PD, and its role in the development of LIDs has been evaluated
in a recent meta-analysis [52•] and in several PET studies [40••,
53–55]. PD patients with LIDs showed a relative preservation of
serotonergic terminals in the putamen, but the administration of
the same levodopa dose induced markedly higher striatal synap-
tic dopamine release, evaluated with [11C]raclopride challenge,
compared with PD patients with stable responses to levodopa.
Oral administration of the serotonin receptor type 1A agonist
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buspirone, a presynaptic modulator of the serotonergic system,
before levodopa administration reduced levodopa-evoked striatal
synaptic dopamine release and attenuated LIDs [40••]. Another
study showed that PD patients with LIDs had no difference in
striatal dopaminergic disease, assessed by [18F]FP-CIT PET,
compared with non-dyskinetic PD patients; however, the
[11C]DASB to [18F]FP-CIT binding ratio (indicating
serotoninergic to dopaminergic terminal availability) was higher
in the putamen of PD patients with LIDs [53]. These findings
were confirmed by another study, which demonstrated that the
SERT to DAT ratio increases as PD progresses and patients ex-
perience LIDs [54]. Overall, these findings suggest that as the
dopaminergic innervation in the striatum becomes critically low,
the serotonergic system plays an important role in development
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of LIDs by handling dopamine synaptic levels in an unregulated
manner. Moreover, the role of the globus pallidus in the devel-
opment of LIDs has been demonstrated also with [11C]DASB
PET. PD patients with LIDs had relative preservation of seroto-
nergic terminals in the globus pallidus and increased pallidal
dopamine release, measured with levodopa challenge and PET
[55]. Serotonergic mechanisms such as excessive striatal inner-
vation and high serotonin to dopamine striatal terminal ratio have
also been associated with the development of graft-induced dys-
kinesias in PD patients who underwent striatal transplantation
with fetal ventral mesencephalic tissue [56–58]. These findings
support the role of serotonergic terminals in the aberrant release
of striatal dopamine and in promoting the development of dys-
kinesias in patients with PD.
Molecular Imaging of the Noradrenergic System
The main presynaptic component of noradrenergic pathways
is from the locus coeruleus projecting to the forebrain, includ-
ing the striatum [59]. As for the serotonergic terminals, the
noradrenergic terminals express AADC and are able to convert
levodopa into dopamine [60]. Increased release of dopamine
via noradrenergic terminals may promote dysregulated striatal
dopamine levels and, consequently, LIDs [61]. A recent ran-
domized clinical trial showed that fipamezole, a selective α2-
adrenergic receptor antagonist, was able to reduce LIDs
without exacerbating parkinsonism [62]. Unfortunately, PET
l i gands fo r no r ad r ena l i n e t r an spo r t e r such a s
2-(α-(2-[11C]methoxyphenoxy)benzyl)morpholine or
[11C]methyl reboxetine are not reliable tools to assess
in vivo noradrenaline transporter activity [63], showing very
low signal in the striatum. The development of selective PET
radioligands tagging the noradrenergic system is warranted to
better understand its involvement in the development of LIDs.
Molecular Imaging of the Cholinergic System
The main presynaptic component of cholinergic pathways is
from the pedunculopontine nucleus pars compacta, projecting
to the forebrain as well as various subcortical structures such
as the thalamus [64]. Post-mortem studies in humans have
shown decreases in acetylcholinesterase activity in PD pa-
tients with and without dementia [65]. PET ligands for the
presynaptic cholinergic system such as N-[11C]methyl-4-
piperidyl acetate ([11C]MP4A) and N-[11C]methylpiperidinyl
propionate ([11C]PMP) are reliable tools to assess in vivo ace-
tylcholinesterase activity [66]. PET studies using [11C]MP4A
and [11C]PMP have demonstrated 11–12% decreases in corti-
cal and subcortical acetylcholinesterase activity in PD patients
without dementia [67, 68]. No PET studies investigating the
role of acetylcholinesterase in the development of LIDs have
been performed in PD patients; thus, this component needs
further investigation.
The main postsynaptic component of cholinergic pathways
is from cholinergic neurons intrinsic to the striatum [69].
Global striatal output is significantly influenced by the cholin-
ergic interneurons [70]. They represent less than 5% of the
total striatal neurons but provide a major contribution to the
release of dopamine [71]. In preclinical studies, elevated cho-
linergic signalling has been associated with LIDs [72], and
muscarinic and nicotinic receptor antagonists partially attenu-
ated the expression of LIDs [73, 74]. LIDs may be attenuated
by the ablation of the striatal cholinergic interneurons, without
affecting the beneficial antiparkinsonian effect of levodopa
[75]. Post-mortem studies in humans showed reduced levels
of muscarinic and nicotinic receptors in the striatum of PD
patients [76, 77]. This potentially suggests a downregulation
of the receptors induced by increased cholinergic signalling.
PET ligands for the postsynaptic cholinergic system such as
[18F]A-85380 and N-[11C]methylpiperidyl benzilate
([11C]NMPB) are reliable tools to assess in vivo nicotinic
and muscarinic receptors respectively. A PET study using
[18F]A-85380 was performed in PD patients and showed re-
duced levels of nicotinic receptors in the striatum and
substantia nigra compared with the levels in controls [78].
There were no associations between [18F]A-85380 levels
and disease severity, but LIDs have not been evaluated in
detail. No PET studies have been performed in humans
Fig. 1 The pathways involved in the development of levodopa-induced
dyskinesia (LID). a In Parkinson’s disease patients with stable response to
levodopa, dopamine transporter (DAT) takes up dopamine and it is stored
in the presynaptic vesicles, via vesicular monoamine transporter 2
(VMAT2). As a consequence, dopamine levels remain relatively stable
in the synaptic cleft, even after levodopa supplementation. Dopamine
levels are maintained within a normal range as serotonergic terminals
do not release dopamine excessively after levodopa supplementation,
and DAT and noradrenaline transporter (NET) continue to take it up. At
the postsynaptic level, the concentrations of dopaminergic, glutamatergic,
adenosinergic, opioid and cannabinoid type 1 receptors are within the
normal range. However, there is a decline in the concentration of
phosphodiesterase 10A (PDE10A), which is an intracellular modulator
of these receptors. b Parkinson’s disease patients with LIDs lack the
capacity to store dopamine, as a result of reduced VMAT2 levels, and
fail to take up dopamine, due to the loss of DAT. This is associated with
increased dopamine levels in the synaptic cleft. Excessive and
inappropriate release of dopamine from serotonergic terminals
contributes to the sharp increase of dopamine concentration after
levodopa supplementation. At the postsynaptic level, the concentrations
of glutamatergic and adenosinergic receptors are increased and those of
opioid receptors are reduced. The concentrations of D1, D2 and
cannabinoid type 1 receptors are within the normal range. Compared
with Parkinson’s disease patients with stable response to levodopa,
there is a further decline of PDE10A concentration, which also
correlates with the severity of dyskinesias. A2A-R adenosine A2A
receptor, CB1-R cannabinoid receptor type 1, D1-R dopamine receptor
D1, D2-R dopamine receptor D2, D3-R dopamine receptor D3, 5HT1A-R
serotonin receptor 1A, NMDA-R N-methyl-D-aspartate receptor, opioid-
R opioid receptor, SERT serotonin transporter
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investigating the role of the cholinergic system in LIDs with
[18F]A-85380, [11C]NMPB or other tracers; thus, this compo-
nent needs further investigation.
Molecular Imaging of the Glutamatergic System
Glutamate is an excitatory neurotransmitter that acts through
glutamateN-methyl-D-aspartate (NMDA) receptors, which in-
clude the NR1, NR2A andNR2B subtypes [79]. Experimental
studies have shown that hyperphosphorylation of these sub-
units is associated with increased glutamatergic neurotrans-
mission and the development of LIDs [80]. PET ligands for
NMDA receptors such as [11C]CNS51619 are reliable tools to
investigate in vivo the glutamatergic system [81]. Only one
PET study investigating the glutamatergic system has been
performed in PD patients with LIDs [81]. PD patients not
receiving medication had no differences in the basal nuclei
and in the motor cortex compared with PD patients with stable
response to levodopa. However, PD patients with LIDs receiv-
ing medication showed higher [11C]CNS51619 uptake in the
caudate, putamen and precentral gyrus compared with PD
patients without LIDs, suggesting that dyskinetic patients may
have abnormal glutamatergic transmission in motor areas
following levodopa administration [81]. These findings support
the hypothesis that glutamate transmission is important in the
development of LIDs, and provide the physiological basis of
why amantadine, a non-competitive antagonist of the NMDA
receptor, is currently the most effective treatment for LIDs [82].
Molecular Imaging of the Adenosinergic System
Adenosine is an endogenous ligand for four receptor subtypes:
A1, A2A, A2B and A3 [89]. The adenosine A2A receptors are
expressed in the striatum and interact with the dopamine D2
receptor function, via the cAMP pathway [83]. PET ligands
for the adenosinergic system such as [1-methyl-11C]8-
dicyclopropylmethyl-1-methyl-3-propylxanthine and [7-
methy l -11C]-(E)-8-(3,4,5-tr imethoxystyryl)-1,3,7-
trimethylxanthine or [11C]SCH442,416 are reliable tools to
measure in vivo A1A and A2A receptors, respectively. Two
PET studies investigating the adenosinergic system have been
performed in PD patients with LIDs [84, 85]. They both
showed increased striatal adenosine A2A receptor availability
in PD patients with LIDs [84, 85]. A2A receptor binding sites
could serve as potential pharmacological targets for the man-
agement of LIDs. A recent randomized clinical trial in PD
patients with LIDs showed that use of KW-6002, a selective
adenosine A2A receptor antagonist, was effective in alleviating
this motor complication [86].
Molecular Imaging of the Opioid System
Three opioid receptors subtypes (μ, κ and δ) are involved in
regulating dopamine functions [87]. [11C]diprenorphine, a non-
selective opioid receptor PET ligand, is a reliable tool to assess
in vivo the opioid system [25]. The main limitation of this tracer
is that it binds all three opioid receptor subtypes with similar
affinity. One PET study has been performed with
[11C]diprenorphine in PD patients, and showed reduced striatal,
thalamic and cingulate opioid receptor binding and increased
prefrontal opioid receptor binding in PD patients with LIDs com-
pared with PD patients with stable response to levodopa [88]. No
correlations were found between [11C]diprenorphine levels and
PD severity, disease duration, or duration of levodopa treatment
[88]. Further PET studies using more selective opioid
radioligands could provide better insight into the role of the opi-
oid system in the pathophysiology of LIDs.
Molecular Imaging of the Cannabinoid System
The cannabinoid type 1 (CB1) receptor is a seven transmem-
brane G-protein-linked receptor located predominantly in the
striatal medium spiny neurons [89]. CB1 receptors inhibit ade-
nylate cyclase by interacting with Gi/o proteins in the direct
pathway, and they counteract D2 inhibition of adenylate cyclase
coupling with Gs proteins in the indirect pathway, thus having a
key role in the control of movement [90]. Alterations in the
availability of the cannabinoid receptors have also been related
to the development of LIDs [91]. PET ligands such as [18F]MK-
9470 are a reliable tool to measure in vivo CB1 receptors [92].
One study has been performed in PD patients, using [18F]MK-
9470, which demonstrated a significant decrease in CB1 recep-
tor availability in the substantia nigra compared with healthy
controls. No correlation was found between reductions in CB1
receptor levels and the severity of LIDs [92]. Further PET stud-
ies with highly selective CB1 receptor radioligands, such as
( 3R , 5R ) - 5 - ( 3 - [ 1 1C ]me t h o x yph e n y l ) - 3 - ( (R ) - 1 -
phenylethylamino)-1-(4-trifluoromethylphenyl)pyrrolidin-2-
one [93], are needed to clarify the role of the cannabinoid sys-
tem in the development of LIDs.
Molecular Imaging of PDE10A
PDE10A is mainly expressed in striatal medium spiny neurons,
where it regulates the cAMP/PKA/DARPP-32 signalling cas-
cade, thus plays a key role in the regulation of the global striatal
output and in promoting neuronal survival [94, 95]. PDE10A has
received increased attention since the observation that its pharma-
cological inhibition in a PD animal model significantly reduced
motor symptoms and LIDs [96]. The PET ligand [11C]IMA107
has been used to quantify PDE10A expression in vivo in
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moderate–advanced PD patients [26]. PD patients showed lower
PDE10A levels in the caudate, putamen and globus pallidus com-
pared with healthy controls. Higher Unified Dyskinesia Rating
Scale scores in PD patients with LIDs correlated with lower
PDE10A levels in the caudate and putamen [26]. This provides
evidence for the role of PDE10Awithin the caudate and putamen
in the development of LIDs in PD. Currently, a clinical trial
(NCT02687542) is evaluating the effect of PDE10A inhibitors
on motor complications in advanced PD patients.
Conclusions
Studies have provided robust evidence that LIDs in PD are asso-
ciated with elevated and fluctuating striatal dopamine synaptic
levels arising from an imbalanced dopaminergic to serotonergic
terminal ratio, with the latter playing a key role in mishandling
presynaptic dopamine release. However, other non-dopaminergic
systems and pathways such as the glutamatergic, adenosinergic
and opioid systems and phosphodiesterase 10A may play impor-
tant roles in the development of LIDs in patients with PD. The
implementation of novel PET ligands is warranted to unveil un-
explored mechanisms of underlying pathophysiology of LIDs,
and applications of multimodal PET molecular imaging ap-
proaches combining different tracers may shed further light on
the mechanisms underlying the development of LIDs in PD.
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